| Mr. (“Hugh”) McNaught, Sr. Advisor Business Development |
Hugh is a senior executive focused on providing transformational leadership to technology ventures. He is recognized for his expertise in developing and commercializing technologies for companies ranging in size from university spin-outs to multinational companies. His experience within the medical and life science sectors includes management roles within Boehringer Mannheim (acquired by Roche), Kodak (Johnson & Johnson) and Amersham (GE).
|
|
Hugh is well versed in corporate governance practices. Expertise includes: Corporate development spanning from pre-incorporation to multinational companies; Technology development and commercialization including management of intellectual property; Finance including private equity, debt, and non-dilutive capital; Due diligence addressing a wide range of technologies and business models. |
| Dr. (“Mike”) E. Shannon, M.A., M.Sc., M.D, Member Scientific Advisory Board |
Mike along with his Medical Degree, holds Masters degrees in both neurophysiology and physiological psychology. Mike served in the Canadian Forces for 31 years retiring at the rank of Commodore (Brigadier General equivalent) as Deputy Surgeon General for The Canadian Forces.
Mike in 1996 assumed responsibilities within Health Canada for re-organizing the Canadian blood system.
Mike has extensive research experience, which includes the directing of a phase III clinical trial in Canada, the United States and Great Britain for an artificial blood substitute product.
|
|
In 2007-08, Mike served on a special assignment to the Canadian Public Health Agency (Center for Disease Control equivalent in the United States) as Senior Medical Advisor. His responsibility was to direct the rebuilding of the Emergency Medical Response Capacity for Canada.
Mike has just succeeded in establishing The Canadian Foundation for Global Health, which in collaboration with the WHO, PAHO and other institutions/ foundations, will be used to advocate for, fund, coordinate and conduct research intended to promote and/or enhance global health. |
| Dr. (“Avi”) Livnat, Member Scientific Advisory Board |
Avi is the Founder and past General Manager of Quintiles Israel Ltd., a wholly owned subsidiary of Quintiles Transnational Inc., the world largest Contract Research Organization. Under his management and during his three years, Quintiles Israel grew to 60 employees, to become the largest company of its kind in Israel. It currently offers a variety of services to the biomedical industry: strategic and regulatory consulting, pre-clinical testing, clinical trials design, management and pharmaco-economics evaluations
Avi founded the Medical Device Department at the Ministry of Health of the State of Israel and was its head for four years. His department performs a similar role to the U.S. Food & Drug Administration. It practices as the safeguard of Safety and Efficacy of Medical Device (FDA-CDRH);
|
|
Modernizing the Pharmaceutical Administration; Establishing international connections and cooperative working relationship with the FDA, Canadian and European authorities. Modernizing the Clinical Trials regulatory system in Israel.
Avi also served as a Professor of Physiology and Biophysics at the University of Illinois at Urbana-Champaign. He holds a B.Sc. from the Hebrew University of Jerusalem in Physics and Mathematics, a Ph.D. from the University of Southern California in Cardiovascular Physiology and Biomedical Engineering and a M.Sc. from the University of Illinois in Economics. |
| Dr. Terry Pearson, Board Member |
Dr. Pearson, Ph.D. is Senior Scientific Advisor to the Plasma Proteome Institute, Washington, DC www.plasmaproteome.org The Institute aims to foster a comprehensive exploration of the proteins of human blood plasma (the plasma proteome) and the rapid application of novel protein measurements in clinical diagnostics. Dr. Pearson is a professor in the Department of Biochemistry and Microbiology at the University of Victoria where he is involved in research on tropical diseases and the use of monoclonal antibodies and mass spectrometry for protein detection in a variety of applications.
Dr. Pearson received his B.Sc. and Ph.D. degrees in microbiology and immunology from the University of British Columbia in Vancouver. After postdoctoral work in tumor immunology at the Medical Research Council Laboratory in Cambridge, England, in the laboratory of Dr. Sydney Brenner, Dr. Pearson worked as a staff scientist in its Division of Cell Biology. While in Cambridge he was involved in the early stages of the development of monoclonal antibody technology with Georges Kohler and Cesar Milstein.
|
|
He was a staff scientist at the International Laboratory for Research on Animal Diseases in Nairobi, Kenya where he introduced monoclonal antibodies to Africa.
Since then his research has focused on the biochemical and immunological analysis of tropical protozoan parasites, mainly trypanosomes, the causative agents of African sleeping sickness. Currently his research team uses protein micro chemical techniques and mass spectrometry as tools for identification of molecular interactions between infectious agents and insect vectors. His research also focuses on development of quantitative mass spectrometric methods for application to clinical diagnostics, an approach that involves development of antibody probes for proteins in deep proteomes such as human plasma. He served as a Trustee of the Terry Fox Medical Research Foundation and as a Director of the Science Council of British Columbia.
Dr. Pearson has published more than 150 scientific articles, many involving monoclonal antibodies and their use in protein identification and characterization. |
Kim Elton, Communications Officer
|
Mr. Elton is a senior marketing and advertising professional with over 30 years of experience in broadcast, film and music production as well as advertising and marketing. He is author of the popular business publication entitled ‘‘Net Benefits,’’ a book about developing marketing strategies using the internet medium.
|
|
He served as VP of Marketing for eCharge Corporation at start up and VP of Net Communications jointly for Celerity Digital Inc. and Evolution USA, Inc.
His consulting firm Elton Communications specializes in strategic marketing programs that utilize the Internet.. |
| Mr. (“John”) McKay, Member Board of Advisors, Business & Science |
Since late 2000, John established JHM PharmaServices to provide consultancy services in Marketing Strategy, Business Development, Product Assessment and Licensing to various large Pharmaceutical and Bio-Pharmaceutical clients. Prior to that John was 20 years with SmithKline Beecham, most latterly as Vice President and Director Global Marketing (formerly Strategic Product Development). In this role he was responsible for the worldwide commercial development of major products and the new product pipeline.
|
|
During his career he has held General Management and Marketing Management positions in Canada, Brazil, Italy, Latin America and China for SmithKline Beecham and for Warner Lambert. Prior to entering the pharmaceutical industry he had experience in science and new product development positions in the animal agriculture industry. John holds Science and Business degrees from Mount Allison University and Queens University in Canada. |
